Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07396168 · ClinicalTrials.gov registry record · Phase 4
Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.
A Phase 4 study of Lichen Plano-Pilaris, sponsored by The Skin Center Dermatology Group.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07396168 is a Phase 4 study of Lichen Plano-Pilaris that is actively recruiting participants, run by The Skin Center Dermatology Group. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07396168, a Phase 4 study of Lichen Plano-Pilaris, is actively recruiting participants, sponsored by The Skin Center Dermatology Group.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.
Conditions Studied
Interventions
- DRUG Nemolizumab
Study Locations (1)
New York
- The Skin Center Dermatology Group - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07396168
The ClinicalTrials.gov registry entry for NCT07396168 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Skin Center Dermatology Group, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lichen Plano-Pilaris appearing as the primary indexed condition, and to 1 intervention - of which Nemolizumab is the first listed.
NCT07396168 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07396168 about?
NCT07396168 is a clinical study titled "Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.". Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inad...
What is the current status of trial NCT07396168?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2026-02-01. Estimated completion is 2027-06.
What conditions does trial NCT07396168 study?
This clinical trial studies the following conditions: Lichen Plano-Pilaris.
What interventions are being tested in trial NCT07396168?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT07396168?
This trial is sponsored by The Skin Center Dermatology Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07396168 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.